Drug screening based on cardiomyocytes derived from FAHXMUi001-A successfully identified verapamil and lidocaine as alternative therapeutic agents for the treatment of a rare KCNQ1/TRPM4 dual mutation long QT syndrome patient. The gene discussed is KCNQ1; the disease is Prolonged QT interval.